Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Seong-Keun, Chowell, Diego, Valero, Cristina, Morris, Luc G. T., Chan, Timothy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990074/
https://www.ncbi.nlm.nih.gov/pubmed/35393553
http://dx.doi.org/10.1038/s41698-022-00267-7
_version_ 1784683308614942720
author Yoo, Seong-Keun
Chowell, Diego
Valero, Cristina
Morris, Luc G. T.
Chan, Timothy A.
author_facet Yoo, Seong-Keun
Chowell, Diego
Valero, Cristina
Morris, Luc G. T.
Chan, Timothy A.
author_sort Yoo, Seong-Keun
collection PubMed
description The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.
format Online
Article
Text
id pubmed-8990074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-89900742022-04-22 Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade Yoo, Seong-Keun Chowell, Diego Valero, Cristina Morris, Luc G. T. Chan, Timothy A. NPJ Precis Oncol Brief Communication The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group. Nature Publishing Group UK 2022-04-07 /pmc/articles/PMC8990074/ /pubmed/35393553 http://dx.doi.org/10.1038/s41698-022-00267-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Yoo, Seong-Keun
Chowell, Diego
Valero, Cristina
Morris, Luc G. T.
Chan, Timothy A.
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
title Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
title_full Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
title_fullStr Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
title_full_unstemmed Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
title_short Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
title_sort pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990074/
https://www.ncbi.nlm.nih.gov/pubmed/35393553
http://dx.doi.org/10.1038/s41698-022-00267-7
work_keys_str_mv AT yooseongkeun pretreatmentserumalbuminandmutationalburdenasbiomarkersofresponsetoimmunecheckpointblockade
AT chowelldiego pretreatmentserumalbuminandmutationalburdenasbiomarkersofresponsetoimmunecheckpointblockade
AT valerocristina pretreatmentserumalbuminandmutationalburdenasbiomarkersofresponsetoimmunecheckpointblockade
AT morrislucgt pretreatmentserumalbuminandmutationalburdenasbiomarkersofresponsetoimmunecheckpointblockade
AT chantimothya pretreatmentserumalbuminandmutationalburdenasbiomarkersofresponsetoimmunecheckpointblockade

Ejemplares similares